J&Js Alza and Scios units to cut jobs

Share this article:

Johnson & Johnson unit Alza plans to eliminate close to 600 jobs in research and development and support by the end of 2007, The Silicon Valley-San Jose Business Journal reports.

Another 200 positions in clinical development, manufacturing, sales and marketing, at both Alza and J&J division Scios will be relocated to other company sites, the newspaper's Web site reported.

News of the cuts came just hours after J&J announced plans to trim its global work force by up to 4% or as much as 4,820 jobs.

Alza was acquired by J&J in 2001 for $10.5 billion and Scios was acquired in 2003 for $2.3 billion. Both companies will vacate their office space in Mountain View, CA by the end of 2007. Alza will seek a buyer for its stake in the property, according to the Web site report. Alza said its 1,200-person facility in Vacaville, CA will continue to operate without disruption. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...